诪讚讬谞讛: 住讬谉
砖驻讛: 住讬谞讬转
诪拽讜专: CFDA (鑽洃灞 - 涓浗椋熷搧鍜岃嵂鐗╃鐞嗗眬)
鐩愰吀宸﹁タ鏇垮埄鍡
婀栧崡涔濆吀鍒惰嵂鑲′唤鏈夐檺鍏徃
R06AE09
Levocetirizine Dihydrochloride
5mg
鑳跺泭鍓
鍙f湇
婀栧崡涔濆吀鍒惰嵂鑲′唤鏈夐檺鍏徃
鏀跺綍绫诲埆: 閫氳繃璐ㄩ噺鍜岀枟鏁堜竴鑷存ц瘎浠风殑鑽搧
涓婂競閿鍞腑
2020-07-24
鏍告牳鏍告牳鏍 鐩愮洂鐩愮洂鐩愮洂鐩愮洂鐩愮洂鐩愮洂 鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍 鐩愮洂鐩愮洂鐩愭牳 鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳 鏍告牳鏍告牳鏍告牳鏍 鏍告牳鏍告牳鏍 Levocetirizine Dihydrochloride Capsules 鏍告牳鏍告牳鏍 Yansuan Zuoxitiliqin Jiaonang 鏍哥洂鐩愭牳 鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍 鏍告牳鏍告牳鏍 (+)-2-[2-[4-[(4- 鏍告牳鏍 ) 鏍告牳鏍 )-1- 鏍告牳鏍 ] 鏍告牳鏍 ] 鏍告牳 路 鏍告牳鏍告牳鏍 鏍告牳鏍告牳鏍告牳 鏍告牳鏍告牳 C 21 H 25 ClN 2 O 3 路2HCl 鏍告牳鏍告牳 461.8 鏍哥洂鐩愭牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳 鏍哥洂鐩愮洂鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳 鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳 鏍哥洂鐩愭牳 5mg 鏍哥洂鐩愮洂鐩愭牳 1 鏍 鏍告牳鏍告牳鏍告牳鏍告牳 2 鏍 鏍告牳鏍告牳鏍告牳鏍 鏍告牳鏍 6 鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍 1 鏍告牳 5mg 鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍 鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳 鏍告牳鏍告牳鏍告牳鏍 鏍告牳鏍告牳鏍告牳 ml/min 鏍 a 鏍告牳鏍告牳鏍告牳鏍 鏍告牳鏍告牳鏍告牳鏍 30-49 鏍 2 鏍告牳鏍告牳 5mg 鏍告牳鏍告牳鏍告牳鏍 < 30 鏍 3 鏍告牳鏍告牳 5mg 鏍 1 鏍 / 鏍 6 鏍 鏍告牳鏍告牳 - 鏍告牳鏍告牳鏍告牳鏍告牳鏍 < 10 鏍告牳鏍 a. _琛琛琛琛琛琛琛 琛CLcr ml_ / _min 琛_ = [ 140 鈭 _琛琛琛 琛 琛_ ] _脳 琛琛琛kg 琛_ 72_脳 琛琛琛琛琛 mg_ / _dl 琛_ _脳_ { 0.85_ 琛琛琛琛琛琛琛 琛_ } 鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍糕滄牳鏍告牳鏍告牳鏍告牳鈥濇牳鏍 鏍告牳鏍告牳 鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍糕滄牳鏍告牳鏍告牳鏍告牳鈥濇牳鏍告牳鏍告牳鏍 鏍哥洂鐩愮洂鐩愭牳 鏍告牳鏍告牳鏍告牳鏍告牳 鏍告牳鏍告牳鏍 鏍告牳鏍告牳鏍 6-11 鏍告牳鏍 1-6 鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告牳鏍告 拽专讗 讗转 讛诪住诪讱 讛砖诇诐